Merck elects Isabel De Paoli as CSO

pharmafile | September 26, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck, appointment 

German pharma firm Merck has appointed Isabel De Paoli to the position of chief science officer in addition to her current position as head of communications.

De Paoli will guide the new Group Strategy and Transformation arms of the business, integrating existing strategy, innovation and digitalisation across the company. She will report to Stefan Oschmann, CEO and chairman of the executive board.

“Over the past year, we’ve started to explore a variety of very promising innovation and digitalisation projects to deliver on our promise as a science and technology,” Oschmann commented. “Going forward, we will integrate those initiatives in a coherent strategy to ensure swift and successful implementation. Isabel De Paoli has built a strong track record in defining strategies and setting up organisations that yield efficient and effective returns – most recently in her role as head of group communications, successfully streamlining the organisation to support strategic objectives of our Healthcare, Life Science and Performance Materials businesses.” 

De Paoli began her career as a consultant, working for the Boston Consulting Group before moving to private equity firm Permira. She joined Merck in 2006 as business development manager, chemicals, advancing to head of strategic planning, oncology in 2009. She held responsibility for group strategy from 2012 until 2015, when she was appointed head of communications.  

Matt Fellows

Related Content

TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment

TILT Biotherapeutics has announced promising preliminary safety and efficacy data from its ongoing phase 1 …

FDA approves Merck’s Winrevair for PAH treatment

Merck, known as MSD outside of the US and Canada, has announced that the US …

Merck shares results for Keytruda in cervical cancer treatment

Merck, known as MSD outside of the US and Canada, has announced positive results from …

Latest content